CHIRON, ORTHO FILE PATENT INFRINGEMENT CLAIM AGAINST UNITED BIOMEDICAL
This article was originally published in The Gray Sheet
Executive Summary
CHIRON, ORTHO FILE PATENT INFRINGEMENT CLAIM AGAINST UNITED BIOMEDICAL, seeking to enjoin UBI from manufacturing and selling its HCV enzyme immunoassay, which is currently pending FDA approval. "UBI's sale in the United States of HCV immunoassays employing C domain antigens covered by the claims of [Patent No. 5,350,671] will constitute knowing and willful infringement of the '671 patent," the suit charges. Chiron and joint venture partner Ortho Diagnostic Systems are plaintiffs in the case against privately held UBI.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.